Harold S Javitz1, Caryn Lerman, Gary E Swan. 1. Center for Health Sciences, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA. harold.javitz@sri.com
Abstract
AIMS: To examine the association of person-specific trajectories of withdrawal symptoms of urge-to-smoke, negative affect, physical symptoms and hunger during the first 7 days after smoking cessation with abstinence at end of treatment (EOT) and at 6 months. DESIGN: Hierarchical linear modeling (HLM) was used to model person-specific trajectory parameters (level, slope, curvature and volatility) for withdrawal symptoms. SETTING: University-based smoking cessation trials. PARTICIPANTS: Treatment-seeking smokers in clinical trials of transdermal nicotine versus nicotine spray (n = 514) and bupropion versus placebo (n = 421). MEASUREMENTS: Self-reported withdrawal symptoms for 7 days after the planned quit date, and 7-day point prevalence and continuous abstinence at EOT and 6 months. FINDINGS: In regressions that included trajectory parameters for one group of withdrawal symptoms, both urge-to-smoke and negative affect were predictive of abstinence while physical symptoms and hunger were generally not predictive. In stepwise regressions that included the complete set of trajectory parameters across withdrawal symptoms (for urge-to-smoke, negative affect, physical symptoms and hunger), with a single exception only the trajectory parameters for urge-to-smoke were predictive. Area under the receiver operator characteristic curve was 0.594 for covariates alone, and 0.670 for covariates plus urge-to-smoke trajectory parameters. CONCLUSIONS: Among a number of different withdrawal symptoms (urge-to-smoke, negative affect, physical symptoms and hunger) urge-to-smoke trajectory parameters (level, slope and volatility) over the first 7 days of smoking cessation show the strongest prediction of both short- and long-term relapse. Other withdrawal symptoms increase the predictive ability by negligible amounts. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
AIMS: To examine the association of person-specific trajectories of withdrawal symptoms of urge-to-smoke, negative affect, physical symptoms and hunger during the first 7 days after smoking cessation with abstinence at end of treatment (EOT) and at 6 months. DESIGN: Hierarchical linear modeling (HLM) was used to model person-specific trajectory parameters (level, slope, curvature and volatility) for withdrawal symptoms. SETTING: University-based smoking cessation trials. PARTICIPANTS: Treatment-seeking smokers in clinical trials of transdermal nicotine versus nicotine spray (n = 514) and bupropion versus placebo (n = 421). MEASUREMENTS: Self-reported withdrawal symptoms for 7 days after the planned quit date, and 7-day point prevalence and continuous abstinence at EOT and 6 months. FINDINGS: In regressions that included trajectory parameters for one group of withdrawal symptoms, both urge-to-smoke and negative affect were predictive of abstinence while physical symptoms and hunger were generally not predictive. In stepwise regressions that included the complete set of trajectory parameters across withdrawal symptoms (for urge-to-smoke, negative affect, physical symptoms and hunger), with a single exception only the trajectory parameters for urge-to-smoke were predictive. Area under the receiver operator characteristic curve was 0.594 for covariates alone, and 0.670 for covariates plus urge-to-smoke trajectory parameters. CONCLUSIONS: Among a number of different withdrawal symptoms (urge-to-smoke, negative affect, physical symptoms and hunger) urge-to-smoke trajectory parameters (level, slope and volatility) over the first 7 days of smoking cessation show the strongest prediction of both short- and long-term relapse. Other withdrawal symptoms increase the predictive ability by negligible amounts. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Timothy B Baker; Megan E Piper; Danielle E McCarthy; Matthew R Majeskie; Michael C Fiore Journal: Psychol Rev Date: 2004-01 Impact factor: 8.934
Authors: Thomas M Piasecki; Douglas E Jorenby; Stevens S Smith; Michael C Fiore; Timothy B Baker Journal: Exp Clin Psychopharmacol Date: 2003-11 Impact factor: 3.157
Authors: Caryn Lerman; Christopher Jepson; E Paul Wileyto; Leonard H Epstein; Margaret Rukstalis; Freda Patterson; Vyga Kaufmann; Stephanie Restine; Larry Hawk; Ray Niaura; Wade Berrettini Journal: Neuropsychopharmacology Date: 2006-01 Impact factor: 7.853
Authors: Joseph C Cappelleri; Andrew G Bushmakin; Christine L Baker; Elizabeth Merikle; Abayomi O Olufade; David G Gilbert Journal: Curr Med Res Opin Date: 2005-05 Impact factor: 2.580
Authors: Jessica D Rhodes; William E Pelham; Elizabeth M Gnagy; Saul Shiffman; Karen J Derefinko; Brooke S G Molina Journal: Psychol Addict Behav Date: 2016-08
Authors: Miguel Ángel Cano; Cho Y Lam; Minxing Chen; Claire E Adams; Virmarie Correa-Fernández; Diana W Stewart; Jennifer B McClure; Paul M Cinciripini; David W Wetter Journal: Exp Clin Psychopharmacol Date: 2014-05-05 Impact factor: 3.157
Authors: Jason D Robinson; Liang Li; Minxing Chen; Caryn Lerman; Rachel F Tyndale; Robert A Schnoll; Larry W Hawk; Tony P George; Neal L Benowitz; Paul M Cinciripini Journal: Psychol Addict Behav Date: 2019-01-07
Authors: Yessenia Castro; Miguel Ángel Cano; Michael S Businelle; Virmarie Correa-Fernández; Whitney L Heppner; Carlos A Mazas; David W Wetter Journal: Drug Alcohol Depend Date: 2014-01-31 Impact factor: 4.492
Authors: Michael S Businelle; Cho Y Lam; Darla E Kendzor; Ludmila Cofta-Woerpel; Jennifer B McClure; Paul M Cinciripini; David W Wetter Journal: Exp Clin Psychopharmacol Date: 2013-02 Impact factor: 3.157